Cost-Effectiveness Analysis of Palivizumab as a Prophylaxis for Respiratory Syncytial Virus (RSV) Infection in High-Risk Late Preterm Infants in the Netherlands
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.286
https://www.valueinhealthjournal.com/article/S1098-3015(13)02191-8/fulltext
Title :
Cost-Effectiveness Analysis of Palivizumab as a Prophylaxis for Respiratory Syncytial Virus (RSV) Infection in High-Risk Late Preterm Infants in the Netherlands
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02191-8&doi=10.1016/j.jval.2013.08.286
First page :
A372
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
271